
Neurofibromatosis is a complex medical condition. It describes the emergence of tumors that can impact the brain, spinal cord, and the nerves that transmit messages from the brain and spinal cord to every other area of the body. The majority of tumors are benign (non-cancerous), while some have the potential to develop into malignant tumors.
Most children with NF1 develop many skin spots by the time they become one year old; these patches are known as café-au-lait spots due to their color. Spots that are greater than 1/4 inch (5 millimeters) across and darker than the surrounding skin . Compared to ordinary children, children with NF1 may take longer to walk, talk, and reach other developmental milestones.
Additionally, they might have
CausesA mutated gene that either develops during pregnancy or is inherited from a parent causes neurofibromatosis type 1. Chromosome 17 contains the NF1 gene. A protein termed neurofibromin, which is produced by this gene, aids in controlling cell division. Neurofibromin is lost as a result of gene alteration. This permits unchecked cell growth.
Risk FactorsA family history is the largest risk factor for neurofibromatosis type 1 (NF1). Approximately 50% of individuals with NF1 have a parent-inherited form of the disease. Individuals with NF1 who have unaffected relatives are likely to have a novel gene mutation.
The inheritance pattern for NF1 is autosomal dominant. This indicates that the mutated gene is 50% likely to be present in any child of a parent with the condition.
ComplicationsEven within the same family, neurofibromatosis type 1 (NF1) complications can differ. Complications usually arise when tumors strain on internal organs or damage nerve tissue.
According to the Indian journal of dermatology, venereology and leprology India is doing research in targeted genetic and molecular therapies in neurofibromatosis.
The purpose of this research was to examine the several targeted genetic and molecular therapies used to treat tumors and other clinical manifestations linked to neurofibromatosis type 1. This study examined twenty-eight trials of treatment modalities, including the most recent developments, that used either targeted gene therapy or molecular level medicines for disorders linked to neurofibromatosis. Among the more recent treatments in this area are tyrosine kinase inhibition, mammalian target of rapamycin inhibition, and mitogen-activated protein kinase kinase inhibition.
Since neurofibromatosis is inherited, there are currently no recognized preventative measures.
Chemotherapy: In order to reduce neurofibromas and relieve a patient's symptoms, chemotherapy drugs function by eliminating cells that divide too quickly. The following chemotherapy medications may be recommended for neurofibromatosis: Vinblastine, carboplatin, methotrexate, ifosfamide, and doxorubicin. Since chemotherapy is systemic (treats the entire body rather than just one portion), it is frequently a good choice for treating neurofibromatosis. Chemotherapy may be a more effective alternative than focused treatments like radiation therapy since neurofibromatosis tumors can develop in numerous areas simultaneously.
Cost Start From USD 600 - USD 700Explore Options
Radiation Therapy: Certain neurofibromatosis complications, including peripheral nerve sheath tumors (malignant tumors that develop in other parts of the body), acoustic neuromas (tumors that develop in the inner ears), and optic nerve gliomas (tumors that develop in the eyes), can be treated with radiation therapy. Although neurofibromas are noncancerous tumors that are typically left untreated unless they are extremely large or painful, they can occasionally be shrunk with radiation therapy.
A medical practitioner will first analyse a patient's personal and family medical history and do a physical examination in order to diagnose neurofibromatosis. In order to identify NF1, the patient's skin is examined for cafe au lait spots.
Additional tests include:
Although there is no cure for NF1, there are medicines that can help control its symptoms. A large number of NF1 patients won't need ongoing care. Some patients return home the same day of surgery, while others may need to stay in the hospital for one to three days, depending on the size and location of the neurofibromatosis. Rehab may be necessary for a full recovery, which could take six months.
The U.S. Food and Drug Administration has approved selumetinib (Koselugo) as a treatment for pediatric plexiform neurofibroma. The medication can reduce a tumor's size. Similar medications are presently undergoing clinical trials in both adults and children.









Bangalore, India
Apollo Hospitals Bannerghatta located in Bengaluru, India is accredited by JCI, NABH. Also listed below are some of the most prominent infrastructural details:

Bangalore, India
HCG Kalinga Rao Road located in Bengaluru, India is accredited by NABH, NABL. Also listed below are some of the most prominent infrastructural details:

Faridabad, India
Sarvodaya Hospital and Research Centre located in Faridabad, India is accredited by NABH, NABL. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Here are some of the reasons for choosing India:
There is currently no treatment that can cause the majority of neurofibromatosis to recede or go away, and the only option to get rid of them once they have grown is through surgery. For children aged 2 and up with NF1 who have plexiform neurofibromatosis that produce symptoms and cannot be surgically removed, the Food and Drug Administration has approved the oral drug selumetinib. A malignant plexiform neurofibroma may require chemotherapy and radiation treatment.
With skilled neurosurgeons and cutting-edge medical technology, India has demonstrated significant success rates in treating neurofibromatosis symptoms. The nation's healthcare institutions offer top-notch treatment alternatives, guaranteeing successful outcomes for many patients.
Yes, many Indian hospitals offer the following for neurofibromatosis treatment:
Always consider the following factors when selecting Indian hospitals:
In general, neurofibromatosis treatment has much improved in India. The success rate largely depends on tumor size and their location. Some neurofibromas can be completely removed surgically while others require both chemotherapy and radiation therapy to keep them under check or to reduce size so that they can be surgically removed.
You must look for any lumps or rubbery bumps on the baby's skin and determine whether the baby is itching. To confirm the diagnosis, a concerned physician should do a physical examination and other tests.
Depending on where they are located, neurofibromatosis, particularly plexiform neurofibromatosis, can grow considerably over time and may put pressure on organs and nerves, resulting in pain, weakness, or functional impairment. Malignant peripheral nerve sheath tumors (MPNSTs), which can develop from pre-existing neurofibromas, are more likely to occur in people with neurofibromatosis. Neurological difficulties such as vision problems (optic nerve gliomas), hearing loss, migraines, seizures, and cognitive deficits might arise depending on the location of tumors. Scoliosis is one of the bone abnormalities that some children with neurofibromatosis may acquire. Neurofibromatosis has been linked to an increased risk of high blood pressure and certain heart problems. Multiple spots on the skin are frequently the most obvious symptom, and they can lead to social anxiety and self-consciousness.
No, we cannot cure neurofibromatosis before birth.
Here are some ways you can take care of your child:
The majority of kids with neurofibromatosis lead normal, full lives with only minor symptoms. A child with neurofibromatosis requires routine examinations so that medical professionals can screen for: